Skip to main content
. Author manuscript; available in PMC: 2023 Sep 5.
Published in final edited form as: Biol Blood Marrow Transplant. 2018 Jul 29;24(12):2479–2486. doi: 10.1016/j.bbmt.2018.07.023

Table 2.

Clinical Outcomes Comparing Differences between Those Subjects Treated with Calfactant and Those Who Received Placebo

Clinical Outcomes Effect Comparison (95% CI)* P
Mortality (PICU discharge): HR 1.78 (.53–6.05) .35
First intervention (outcome = OI)
 Treatment × time interaction .64
Second intervention (outcome = OI)
 Treatment × time interaction .52
Deterioration in POPC score: OR .57 (.11–2.85) .49
Deterioration in PCPC score: OR .45 (.09–2.22) .33
Retreated (received the second intervention): OR .44 (.08–2.35) .34
Expected no. of VFDs: RR 1.11 (.88–1.41) .37
Unsuccessful extubation§: OR .58 (.12–2.77) .50

HR indicates hazard ratio; OR, odds ratio; RR, rate ratio.

*

All effects compare the calfactant group with the placebo group.

Adjusted for risk strata + PRISM score.

Adjusted for risk strata.

§

Defined as free from mechanical ventilation for greater than 48 hours.